S H Kelkar Targets 40%+ Gross Margin in 1H FY27

S H Kelkar and Company Limited — Q4 & FY26 Earnings Call (held May 18, 2026)

1. Overall Tone of Management: Neutral (leaning Optimistic)

• Management highlights “steady progress” and “encouraging revenue growth” with “resilient demand.”
• However, they repeatedly emphasize a “dynamic” environment, “highly dynamic” raw material pricing, and avoid full-year certainty (“difficult question… not really in a position to give you a full-year view”).
• Tone is confident on near-term execution (1H FY27) but cautious beyond that.

2. Key Themes from Management Commentary

• Platform build for next phase of growth
• Creative Development Centres (CDCs) are now “playing an active role” in product development and customer engagement.
• Management expects CDCs to “meaningfully transform our business profile over time,” with higher quality/higher margin growth.
• Capacity expansion to remove bottlenecks
• Almere (Netherlands) greenfield is “fully operational,” debottlenecking Europe.
• Vanavate (Maharashtra) expected “in the coming months.”
• Vashivali rebuilding referenced as part of ensuring capacity “for the foreseeable future.”
• Margin protection amid volatile RM inflation
• Portfolio optimization: exited “~INR 35 crores of low-margin products” via one-off sale.
• Strategy: “protecting margins” while ensuring “supply security.”
• Pricing and supply continuity are managed tightly due to rapid RM price changes (“even by the next day”).
• Cash generation / balance sheet focus
• Acknowledges temporary inventory build and “short-term increase in borrowing levels,” but medium-long term focus is “cash generation… reducing debt.”
• Near-term visibility vs longer-term uncertainty
• Management is confident for Q1/Q2 and “first half,” but beyond that they stress uncertainty in RM supply/pricing and inflation.

3. Q&A Analysis

Theme A: Capex/CDC investments, payback, and margin trajectory

• Core questions
• How long until capex/CDC investments generate returns and what are the losses/costs at the CDC level?
• When do margins normalize (teens / low-teens) and what is the timeline?
• Management response
• CDC opex treated like capex: “2 to 3 years before we start to generate revenue.”
• CDC investment cost cited: “Rs. 80 crore to Rs. 85 crore annually” (described as cost center producing samples, not “losses”).
• Margin normalization: guided to “normalize towards the teens… Yes… we will reach there quickly” (but also later ties confidence mainly to first half).
• Notable signals
• Strong framing of investment logic (“markets which are 20x bigger”), but also admits longer-than-1–2-year realization (“it will take longer than that”).
• No hard quantitative ROCE/EBITDA bridge provided in this call despite earlier historical mentions of detailed plans.

Theme B: Raw material inflation, inventory strategy, and gross margin stability

• Core questions
• Impact of RM price increases (including citrus terpenes/crude derivatives) and whether they’ll repeat prior inventory/EBITDA lag.
• Can they maintain gross margin (e.g., 40% gross margin) in 1H?
• Management response
• Inventory pricing inflation: “upwards of 12%, 13% plus” across operations/power/fuel.
• Inventory approach: “2 to 3 months of inventory… in hand” and reset pricing every 2–3 months to avoid mismatch.
• Gross margin confidence: “for the first half… maintain this margin… 40% plus gross margin.”
• They claim they avoided the prior lag: “Not really” expecting a repeat of the old inventory pile-up effect.
• Notable signals
• Some hedging on exact numbers (“very difficult to put an exact number”).
• Explains margin dips in March due to buying solvents at market prices (“shot up”), implying margin volatility persists.

Theme C: US/Europe ramp-up timelines, break-even, and competitive dynamics

• Core questions
• US profitability timeline at EBITDA and PAT levels; break-even timing.
• Europe optimal utilization timeline and which countries/geographies will grow.
• Whether anti-trust outcomes could enable co-ownership/IP tie-ups with FMCG players.
• Management response
• US: organic break-even “roughly 4 years or earlier” (in contrast to inorganic 5–6 years).
• US orders: “business in the US upwards of 1 million contracted” and already converting.
• Europe: Almere day-one operational with “10 million yearly sale”; growth regions include “Northern Europe, East Europe, Poland, Germany, and Belgium.”
• Anti-trust: they see buyers seeking alternatives; but deny core co-ownership/IP sharing: “not our core business” and “we are doing a bit… in Europe in a tolling manufacturing.”
• Notable signals
• Competitive advantage framed as “disturbances are good opportunities.”
• No concrete PAT timeline; answers focus on EBITDA and qualitative competitiveness.

Theme D: Demand environment, growth acceleration, and FX impact

• Core questions
• Is demand weakening in India/Europe? Any acceleration expectations for FY27?
• How much FX contributed to revenue growth and whether rupee depreciation pressures margins?
• Management response
• India: “demand… no demand per se reduction,” but shipment delays around March caused “slight volume drop.”
• Europe: muted growth attributed to prior capacity constraints; new capacity should restore “double-digit plus growth.”
• FX: revenue gain “3% to 3.5%”; margin pressure due to “dollar loan… translation impact,” otherwise revenue transactions neutral.
• Notable signals
• They reconcile ROW growth vs March disruption by clarifying Middle East growth continued; India vs Middle East separation is emphasized.

Theme E: FY27 guidance: EBITDA/margins, capex, debt, and cash conversion

• Core questions
• Can they maintain adjusted EBITDA margin around 13%+? Any full-year guidance?
• FY27 capex, borrowings, cash conversion cycle (CCC).
• Whether FY27 can recover earlier EBITDA targets.
• Management response
• Margin: confident for first half; “very confident” to maintain adjusted EBITDA “current level.”
• Explicit capex/debt:
  • FY27 capex: “around Rs. 140 crore”
  • Borrowings: “around Rs. 800 crore mark”
• CCC: “around 140 days…” and expected to remain until inflation steadies.
• Debt reduction target: “reduce… by 10% every passing year” (interim may rise 3–6 months).
• On EBITDA recovery: one analyst asked about FY27 target vs slip; management said “confident that we will hit the Rs. 300 crore plus EBITDA for this year.”
• Notable signals
• They avoid full-year certainty on margins due to RM supply/pricing uncertainty.
• CCC guidance suggests working capital remains a headwind.

Theme F: Employee/depreciation cost increases and missing margin plan details

• Core questions
• Why employee and depreciation costs still rising despite CDC investments being “done”?
• Prior call mentioned a plan to move adjusted EBITDA margins from 13% to 17%—why not detailed yet?
• Management response
• Employee cost: sequential increase largely explained by one-off MTM impact (~Rs. 6 crore) and normal run-rate (~Rs. 94–95 crore quarterly).
• Depreciation: reclassification (~Rs. 5–6 crore) from other expenses.
• Margin plan: they say environment changed post “07th or 10th of March,” so focus shifted to quarter-on-quarter delivery; longer-term strategy unchanged.
• Notable signals
• This is a credibility/consistency pressure point: they acknowledge delay in providing the detailed margin bridge.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Adjusted EBITDA / margin
• Adjusted EBITDA margin “13.5%” referenced as steady sequentially in FY26; for FY27:
• “For the first half… very confident” to maintain adjusted EBITDA at current level (multiple confirmations).
• Analyst follow-up: “13% to 14%” in a normal environment; management also said “we will reach [teens] quickly” and “maintain… 40% plus gross margin” in 1H.
• FY27 capex
• “around Rs. 140 crore” (front-ended in first two quarters).
• FY27 borrowings
• “Borrowing should remain around the Rs. 800 crore mark.”
• Debt reduction target
• “reduce… by 10% every passing year” (with interim rise possible).
• Cash conversion cycle
• “around 140 days at the moment” and expected to remain until inflation stabilizes.
• EBITDA recovery
• “confident that we will hit the Rs. 300 crore plus EBITDA for this year” (FY27).

Implicit signals (qualitative)

• Full-year outlook uncertainty
• Management repeatedly avoids full-year margin certainty due to “uncertain future” on RM supply and pricing (Iran–USA standoff referenced).
• Pricing power / pass-through
• Strong emphasis on ability to pass on RM increases via contracts and frequent pricing resets.
• Demand
• Demand described as resilient but “muted” overall; growth expected to be supported by market share gains and new capacity ramp.

5. Standout Statements (most revealing)

• On avoiding margin lag from inventory build
• “Not really” expecting a repeat of prior inventory/EBITDA normalization delays.
• On CDC economics
• CDCs are “to the tune of Rs. 80 crore to Rs. 85 crore annually” and “will take 2 to 3 years before we start to generate revenue.”
• On near-term visibility
• “We are not really in a position to give you a full-year view” but “we are on track for a normal quarter 1” and “no cause for concern for the first half.”
• On margin normalization
• “Yes… we will reach there quickly” (teens/low-teens), but later ties confidence mainly to 1H.
• On portfolio optimization
• Exited “~INR 35 crores of low-margin products” and continues monitoring for structurally low-margin/long lead-time businesses.
• On capex/debt tradeoff
• Acknowledges temporary borrowing/inventory build: “temporarily result in some inventory build-up and a short-term increase in borrowing levels.”

6. Red Flags / Positive Signals

Red flags
– Guidance opacity / hedging
– Avoids full-year view; relies heavily on “wait and watch” beyond 1H.
– Credibility pressure from delayed margin bridge
– Prior call referenced a detailed plan to move margins (13%→17%); in this call they say they’ll “come back” and focus shifted due to March environment change.
– Working capital headwind
– CCC remains high: “around 140 days,” implying cash conversion may not improve quickly.
– Margin volatility acknowledged
– March solvent/material price spike caused “small dip” in margin.

Positive signals
– Concrete operational milestones
– Almere “fully operational” and Vanavate expected soon; Europe debottlenecking narrative is tangible.
– Pricing discipline
– Frequent inventory-based pricing resets and contract pass-through.
– Demand resilience
– Multiple confirmations that demand is not structurally down; disruptions are timing-related.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Q4/FY25 (May 2025): Optimistic—management guided 12%+ CAGR and expected margin recovery; described stabilization post raw material improvement.
• Q2/H1 FY26 (Nov 2025): Still constructive—expected margin improvement and guided EBITDA margin improvement; emphasized investments as “building blocks.”
• Q3/9M FY26 (Feb 2026): More execution/cash discipline focus; still confident but acknowledged investment phase and near-term debt increase.
• Current Q4/FY26 (May 2026): More cautious/defensive than earlier calls:
• Stronger emphasis on “dynamic” RM environment and inability to give full-year view.
• Portfolio optimization and margin protection become more central than growth acceleration.

Shift classification: More Cautious (relative to earlier optimism), especially on forward visibility.

b. Tracking Past Commitments vs Outcomes

• Past statement (Q2/H1 FY26, Nov 2025): “As these initiatives contribute… we expect margins and profitability to substantially improve” over 15–18 months; also “18% to 20% EBITDA by FY ’27” referenced in Q&A.
• What was expected: clearer margin expansion path and improvement by FY27.
• What happened / current call: management now emphasizes maintaining 1H margins and “wait and watch” beyond; no detailed 13%→17% bridge delivered in this call.
• Flag: ⏳ Delayed / Not fully delivered in communication (less specificity than earlier).
• Past statement (Q3/9M FY26, Feb 2026): CDC investments expected to translate into stronger growth; confidence on margin improvement trajectory.
• Current call: confirms CDCs are still a cost center for 2–3 years; reinforces longer gestation.
• Flag: ⏳ Delayed realization (consistent with earlier gestation, but less “near-term improvement” confidence).
• Past statement (Q4/FY25, May 2025): margin recovery expected as raw material availability improves; EBITDA margin recovery framed as transient.
• Current call: margin protection now tied to portfolio exit and inventory-based pricing; suggests margin recovery is not straightforward.
• Flag: ❌ Missed/under-delivered on smooth recovery narrative (more structural actions now).

c. Narrative Shifts

• From growth-first to margin-protection-first
• Earlier calls emphasized growth momentum and margin recovery from raw material normalization.
• Now, portfolio optimization (“exit low-margin business”) and contract-based pricing resets dominate the narrative.
• From “margin improvement will happen” to “visibility limited beyond 1H”
• Current call explicitly limits full-year certainty due to RM supply/pricing uncertainty.
• Europe capacity constraint explanation becomes central
• Earlier: muted Europe due to softness/capacity.
• Now: Europe growth expected to “restore double-digit plus” because Almere is operational.

d. Consistency & Credibility Signals

• Medium credibility
• Operational milestones (Almere operational, Vanavate timeline) are consistent and specific.
• But credibility is weakened by:
  • delayed delivery of detailed margin bridge (13%→17% plan not shown),
  • repeated “dynamic environment” hedging that reduces forecast confidence,
  • CCC staying high and debt remaining elevated despite prior expectations of improvement.

e. Evolution of Key Themes

• Demand: Stable/resilient but “muted” overall in inflationary environment (deterioration in growth rate, not in demand existence).
• Margins: Shift from “improving with raw material cycle” to “actively protected via portfolio exit + pricing discipline.”
• Expansion: Still a core theme; capacity additions now framed as the main lever for Europe growth.
• Cash/debt: Increasing emphasis on cash generation and debt reduction target, but near-term borrowing remains elevated.

f. Additional Insights (cross-period)

• Portfolio optimization appears to be a structural response, not just a one-off
• The “INR 35 crore low-margin exit” is framed as part of ongoing monitoring; suggests margin pressure may persist longer than earlier “raw material cycle” narratives implied.
• Management’s confidence is increasingly time-bucketed
• Strong confidence for 1H, weaker for full-year—indicates uncertainty is not merely execution risk but macro/RM risk.